Dasiglucagon

Summary

Dasiglucagon (Zegalogue) is a room-temperature stable glucagon analog approved for the treatment of severe hypoglycemia in adults and pediatric patients (6 years and older) with diabetes. It offers convenience over traditional glucagon kits due to its stability in aqueous solution without reconstitution.

Mechanism of Action

Dasiglucagon is a stable glucagon receptor agonist that activates hepatic glucagon receptors, stimulating glycogenolysis and gluconeogenesis, thereby rapidly increasing blood glucose levels. It is a chemically modified glucagon analog with improved aqueous stability at room temperature.

Routes of Administration

Goals & Uses

• Severe hypoglycemia rescueGlycemic Emergency ManagementHigh
• Hypoglycemia treatment in congenital hyperinsulinismEndocrine Disorder ManagementModerate
• Prevention of exercise-induced hypoglycemiaHypoglycemia PreventionLow

Contraindications

• Prolonged fasting or starvationNutritionalModerate
• InsulinomaEndocrine TumorHigh
• PheochromocytomaEndocrine TumorHigh
• GlucagonomaEndocrine TumorHigh
• Hypersensitivity to dasiglucagon or excipientsAllergyHigh

Adverse Effects

• HypertensionCardiovascularUncommonHigh blood pressure
• Injection site reactionsLocalCommon
• Hypersensitivity/anaphylaxisImmunologicalRare
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• VomitingGastrointestinalCommonForceful expulsion of stomach contents

Drug Interactions

• InsulinLowMay increase risk of low blood sugar
• Beta-blockersModerate
• WarfarinModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Adrenal insufficiencyEndocrineRelative
• Children under 6 years of agePediatricAbsolute

Regulatory Status

• European UnionApprovedApproved: Severe hypoglycemia in adults and pediatric patients ≥6 years with diabetesEMA approved under the brand name Zegalogue; Zealand Pharma markets in select European countries.
• United StatesApprovedApproved: Severe hypoglycemia in adults and pediatric patients ≥6 years with diabetesFDA approval granted March 22, 2021 (NDA 213436). Available as 0.6 mg/0.6 mL autoinjector and prefilled syringe.
• United KingdomUnknownPost-Brexit regulatory status uncertain; approval may follow EU decision via MHRA.

Approved by the FDA in March 2021 for treatment of severe hypoglycemia. Available as a single-dose autoinjector and prefilled syringe. Developed by Zealand Pharma.

Evidence & Sources

No sources recorded yet.